MDCO stock forecast
Our latest prediction for The Medicines Co.'s stock price was made on the Dec. 17, 2018 when the stock price was at 18.00$.
In the short term (2weeks), MDCO's stock price should outperform the market by 2.83%. During that period the price should oscillate between -8.53% and +11.65%.
In the medium term (3months), MDCO's stock price should outperform the market by 0.74%. During that period the price should oscillate between -19.01% and +28.13%.Get email alerts
Create a solid portfolio with MDCO
About The Medicines Co.
The Medicines Co. is a biopharmaceutical company, which focuses on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on acute and intensive care hospitals worldwide. The firm markets its brands Angiomax, Cleviprex, injectable emulsion, Ionsys, Kengreal, Minocin for injection, and Orbactiv. The company was founded by Clive A. Meanwell, Helmut Giersiefen, John W. Villiger and T. Scott Johnson on July 31, 1996 and is headquartered in Parsippany, NJ.
At the moment the company generates 15M USD in revenues.
On its last earning announcement, the company reported a loss of -3.50$ per share.
The book value per share is 0.28$
Three months stock forecastDec. 17, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|